Since a mild/moderate reduction in BP was also associated with reduction in stroke recurrence and since numerous non-BP lowering effects of ACE inhibition may translate into antithrombotic/fibrinolytic and plaque stabilizing properties, besides actively enhancing the collateral circulation through increased AT2 receptors, there is adequate scientific basis to test these drugs as agents modifying stroke outcomes. The gene discussed is ACE; the disease is stroke disorder.